SynchroMed Infusion System; Ascenda Intrathecal Catheters
Medtronic, Inc. · Decision date Aug 8, 2026
What did the FDA decide?
FDA records P860004/S459 as a supplement to PMA P860004, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 8, 2026.
FDA approval order statement
to update acceptance criteria for printed wiring boards
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General Hospital
- Decision date
- Aug 8, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P860004/S459
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- LKK
- Decision code
- OK30
- Decision date
- Aug 8, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pump, infusion, implanted, programmable.
- Applicant
- Medtronic, Inc.
- Product code
- LKK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P860004. Subsequent supplements may change the device or its indications.
FDA decision timeline
P860004 · Original PMA
MEDTRONIC(R) SYNCHROMED(TM) PUMP & INFUSION SYSTEM
P860004/S445 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters
P860004/S446 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters
P860004/S447 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters
P860004/S448 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters
P860004/S449 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters
P860004/S450 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters (Drug Delivery Infusion Pump 8667); (Drug Delivery Infusion
P860004/S452 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters
P860004/S451 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters
P860004/S454 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters
P860004/S453 · Related supplement
SynchroMed Infusion Systems
P860004/S455 · Related supplement
SynchroMed Infusion System; Ascenda Intrathecal Catheters
P860004/S443 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters
P860004/S457 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters (Drug Delivery Infusion Pump 8667)
P860004/S456 · Related supplement
Drug Delivery Infusion Pump Model 8667
P860004/S459 received
Application receipt date recorded by FDA.
P860004/S459 · FDA decision
30-Day Notice
P860004/S460 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters
P860004/S461 · Related supplement
SynchroMed III Pump Drug Delivery Infusion Pump
P860004/S462 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters
P860004/S458 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters
P860004/S464 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters TDD (Drug Delivery Infusion Pump 8667), TDD (Drug Delivery I
P860004/S465 · Related supplement
SynchroMed Infusion System, Ascenda Intrathecal Catheters
Timeline entries are records held by MedtechLedger for P860004. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P860004
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Mar 14, 1988 | FDA | |
| Medtronic, Inc. | PMA supplement | Jul 17, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Jul 17, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Aug 28, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Aug 29, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Sep 5, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Sep 18, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 16, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Nov 13, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Nov 26, 2025 | FDA | |
SynchroMed Infusion SystemsP860004/S453 | Medtronic, Inc. | PMA supplement | Dec 19, 2025 | FDA |
| Medtronic, Inc. | PMA supplement | Dec 22, 2025 | FDA | |
| Medtronic, Inc. | PMA supplement | Jan 20, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Feb 6, 2026 | FDA | |
Drug Delivery Infusion Pump Model 8667P860004/S456 | Medtronic, Inc. | PMA supplement | Feb 12, 2026 | FDA |
| Medtronic, Inc. | PMA supplement | Aug 13, 2026 | FDA | |
SynchroMed III Pump Drug Delivery Infusion PumpP860004/S461 | Medtronic, Inc. | PMA supplement | Aug 21, 2026 | FDA |
| Medtronic, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 27, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 30, 2026 | FDA |
Explore the linked device profile
Other records with product code LKK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MEDSTREAM PROGRAMMABLE INFUSION PUMP SYSTEMP890055/S093 | Intera Oncology | PMA supplement | Mar 16, 2026 | FDA |
lntera 3000 Hepatic Artery Infusion PumpP890055/S092 | Intera Oncology | PMA supplement | Feb 26, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 7000 Central Ave., NE, Minneapolis, MN, 55432
Sources and methodology
- Original FDA record: P860004/S459
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




